ALZN
NASDAQAlzamend Neuro Inc.
Price$1.15-0.83 (-41.92%)
2026-02-272026-06-02
News · 26 weeks15-100%
2025-12-072026-05-31
Mix990d
- SEC Filings5(56%)
- Other3(33%)
- Insider1(11%)
Latest news
25 items- SECAlzamend Neuro Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- INSIDERSEC Form 4 filed by Ault Milton C Iii4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- PRAlzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General HospitalPotentially Distinct Brain Profile: Across multiple brain regions, AL001 and lithium carbonate appeared to trend in opposite directions in brain chemistry measures, suggesting that AL001 may interact with the brain in a distinct manner and generate a lower neurochemical footprint than lithium carbonateExpected Trends for Myo-Inositol Reduction: Both AL001 and lithium carbonate showed a trend toward reducing myo-inositol, potentially supporting the hypothesis that AL001 retains lithium's core mechanism of actionPotentially Preserved Glutamate Balance: Lithium carbonate showed large effects across all brain regions whereas AL001 showed minimal glutamate effect in most brain regions, which may
- PRAlzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain RegionsBioequivalence Confirmed: AL001 delivered 101% of total lithium blood exposure and 97% of peak lithium levels vs. standard lithium carbonateSuperior Brain Penetration: AL001 showed numerically higher lithium concentrations in all measured brain regions, including whole brainFaster Brain Uptake: AL001 reached peak brain concentration in 6.7 hours vs. 8.4 hours for standard lithium carbonateATLANTA, March 26, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-trauma
- SECAlzamend Neuro Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- PRAlzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General HospitalHead-to-head studies of AL001 versus marketed lithium carbonate will compare lithium blood and brain/brain-structure pharmacokinetics in bipolar disorder type 1 patientsTopline data expected in third quarter of 2026Topline data from the clinically completed "lithium in brain" imaging study in healthy subjects expected by the end of March 2026ATLANTA, March 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced the initi
- SECSEC Form 10-Q filed by Alzamend Neuro Inc.10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECSEC Form 424B5 filed by Alzamend Neuro Inc.424B5 - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECAlzamend Neuro Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECSEC Form DEFA14A filed by Alzamend Neuro Inc.DEFA14A - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECSEC Form DEF 14A filed by Alzamend Neuro Inc.DEF 14A - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECSEC Form PRE 14A filed by Alzamend Neuro Inc.PRE 14A - Alzamend Neuro, Inc. (0001677077) (Filer)
- INSIDERDirector Ault Milton C Iii sold $3,825 worth of shares (1,851 units at $2.07), closing all direct ownership in the company (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- INSIDERDirector Horne William B. sold $7,059 worth of shares (3,333 units at $2.12), closing all direct ownership in the company (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- SECSEC Form 10-Q filed by Alzamend Neuro Inc.10-Q - Alzamend Neuro, Inc. (0001677077) (Filer)
- SECAlzamend Neuro Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- INSIDERDirector Mcgrath Lynne Fahey sold $69 worth of shares (30 units at $2.29), decreasing direct ownership by 55% to 25 units (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- SECAlzamend Neuro Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- INSIDERDirector Ault Milton C Iii converted options into 61,743 shares and sold $294,548 worth of shares (121,791 units at $2.42) (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- SECAlzamend Neuro Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Alzamend Neuro, Inc. (0001677077) (Filer)
- INSIDERDirector Ault Milton C Iii sold $344,222 worth of shares (139,412 units at $2.47) and converted options into 200,000 shares (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Alzamend Neuro Inc.SCHEDULE 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Alzamend Neuro Inc.SCHEDULE 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
- INSIDERDirector Ault Milton C Iii converted options into 100,000 shares and sold $296,789 worth of shares (123,366 units at $2.41) (SEC Form 4)4 - Alzamend Neuro, Inc. (0001677077) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Alzamend Neuro Inc.SCHEDULE 13D/A - Alzamend Neuro, Inc. (0001677077) (Subject)
ALZN FAQ
7 questionsWhat does Alzamend Neuro Inc. do?
Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.Where does ALZN stock trade?
Alzamend Neuro Inc. (ALZN) is listed on NASDAQ.What sector and industry is ALZN in?
Alzamend Neuro Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Alzamend Neuro Inc. go public?
Alzamend Neuro Inc. (ALZN) completed its IPO in 2021.What are analysts saying about ALZN?
Alzamend Neuro Inc. has had 1 recent analyst action on file. The most recent action was from Ascendiant Capital Markets: Buy with a $800.00 price target on 2021-10-01. Recent price targets cluster around $800.00.What companies are similar to ALZN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ALZN side-by-side with any of them on Quantisnow.How can I track ALZN on Quantisnow?
Quantisnow aggregates Alzamend Neuro Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALZN to receive live email and push alerts on every new disclosure.